mvt-5873
mAbexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02672917)
Timeline
Indications
Mechanism of action
- Sialyl Lewis A (CA19-9)BINDING AGENT
Sialyl Lewis A (CA19-9) binding agent
Binds the sialyl Lewis A oligosaccharide antigen.
- Lewis Y antigenImmunity, passive
Lewis Y antigen immunity, passive
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297791 ↗
Also known as
- mvt-5873
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04883775 | Phase 1 | May 10, 2021 | Biontech, Memorial Sloan-Kettering Cancer Center |
| NCT03801915 | Phase 2 | Jul 5, 2019 | National Cancer Institute (NCI) |
| NCT02687230 | Phase 1 | Jul 1, 2016 | MabVax Therapeutics, Inc., SciQuus Oncology |
| NCT02672917 | Phase 1 | Jan 1, 2016 | MabVax Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MabVax Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2016 |
| Biontech | For profit | 1 | 0 | 1 | 2021 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2019 |
| SciQuus Oncology | For profit | 1 | 0 | 1 | 2016 |
5 organizations
Page 1 / 1